Interim safety data from a post-authorization study of Luxturna in patients with genetic retinal diseases were consistent with clinical trial data, according to a presentation at the American Society of Retina Specialists annual meeting.
Aaron Nagiel, MD, PhD, said the post-authorization safety study was designed to collect long-term safety information in patients treated with Luxturna (voretigene neparvovec-rzyl, Spark Therapeutics).
“Voretigene neparvovec is really a success story in gene therapy,” he said. “It’s the first FDA-approved AAV-based gene therapy.”